ReviewPharmacology & therapeutics2020
Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities.
Review in Pharmacology & therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 58 citations in OpenAlex.
- The angiotensin receptor blocker, losartan, reduces inflammation and fibrosis, and prevents relapse of fibrosis after steroid-induced remission, in mice prone to Crohn's disease-like ileitis.Journal of Crohn's & colitis · 2025Article
- Vitamin D as an Adjuvant Immune Enhancer to SARS-Cov-2 Vaccine.Current microbiology · 2025Article
- Role of Natural Products against the Spread of SARS-CoV-2 by Inhibition of ACE-2 Receptor: A Review.Current pharmaceutical design · 2024Review
- Review
- Myocardial injury and related mortality in hospitalized patients with COVID-19 during the Omicron pandemic: new perspectives and insights.Virologica Sinica · 2023Article
- Renin-Angiotensin System Inhibitors and the COVID-19 Pandemic.American journal of hypertension · 2023Article
- Wuhan 3 years after the outbreak of the pandemic-cardiological insights and perspectives.Herz · 2023Review
- Effect of renin angiotensin blockers on angiotensin converting enzyme 2 level in cardiovascular patients.BMC pharmacology & toxicology · 2023Article
- Association between angiotensin-converting enzyme inhibitor-induced cough and the risk of lung cancer: a Mendelian randomization study.Frontiers in pharmacology · 2023Article
- Regulation of SARS-CoV-2 infection by diet-modulated gut microbiota.Frontiers in cellular and infection microbiology · 2023Review
- When the clock ticks wrong with COVID-19.Clinical and translational medicine · 2022Review
- Initiation of antihypertensive drugs to patients with confirmed COVID-19-A population-based cohort study in Sweden.Basic & clinical pharmacology & toxicology · 2022Article
- Risk factors for myocardial injury at admission of 325 patients with coronavirus disease 2019 in Shanghai, China.Australasian journal on ageing · 2022Article
- Significance of Immune Status of SARS-CoV-2 Infected Patients in Determining the Efficacy of Therapeutic Interventions.Journal of personalized medicine · 2022Review
- Global conserved RBD fraction of SARS-CoV-2 S-protein with T500S mutation in silico significantly blocks ACE2 and rejects viral spike.Translational medicine communications · 2022Article
- Small molecule angiotensin converting enzyme inhibitors: A medicinal chemistry perspective.Frontiers in pharmacology · 2022Review
- The Effects of Different Classes of Antihypertensive Drugs on Patients with COVID-19 and Hypertension: A Mini-Review.International journal of hypertension · 2022Review
- Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension.Nature reviews. Cardiology · 2021Review
- Vitamin D and immuno-pathology of COVID-19: many interactions but uncertain therapeutic benefits.Expert review of anti-infective therapy · 2021Review
- Cardiovascular Involvement in Patients with 2019 Novel Coronavirus Disease.Journal of translational internal medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
The coronavirus disease 2019 (COVID-19) pandemic is caused by a newly emerged coronavirus (CoV) called Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). COVID-19 patients with cardiovascular disease (CVD) comorbidities have significantly increased morbidity and mortality. The use of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor type 1 blockers (ARBs) improve CVD outcomes; however, there is concern that they may worsen the prognosis of CVD patients that become infected with SARS-CoV-2 because the virus uses the ACE2 receptor to bind to and subsequently infect host cells. Thus, some health care providers and media sources have questioned the continued use of ACE inhibitors and ARBs. In this brief review, we discuss the effect of ACE inhibitor-induced bradykinin on the cardiovascular system, on the renin-angiotensin-aldosterone system (RAAS) regulation in COVID-19 patients, and analyze recent clinical studies regarding patients treated with RAAS inhibitors. We propose that the application of RAAS inhibitors for COVID-19 patients with CVDs may be beneficial rather than harmful.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.